NCT04587219Unknown2 期
An Open Study of the Safety, Tolerability and Immunogenicity of the "Gam-COVID-Vac"Vaccine Against COVID-19 (Solution for Intramuscular Injection) With the Participation of Volunteers in the Age Group Over 60 Years
Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation1 个研究点 分布在 1 个国家目标入组 110 人开始时间: 2020年10月22日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 入组人数
- 110
- 试验地点
- 1
- 主要终点
- Number of Participants With Adverse Events
研究概览
简要总结
The purpose of this study: to assess the safety, tolerability and immunogenicity of the drug "Gam-COVID-Vac", a solution for intramuscular injection, at various times after vaccination in volunteers over 60 years of age
详细描述
An open-ended prospective non-randomized study involving volunteers over the age of 60.
The study will include 110 volunteers. who will receive the test drug according to the prime-boost scheme: the introduction of component 1 will be carried out on the 1st day, and component 2 - on the 21st day of the study. Outpatient monitoring will be performed during 4 visits: on the 7th, 14th, 28th, and 42nd days after the vaccine administration Also two visits will be performed in the phone contact mode for 90 and 180 days
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 60 Years 至 111 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •The written informed consent of the subject for participation in the study;
- •Men and women over the age of 60 years inclusive;
- •Negative result of research on HIV, hepatitis, syphilis;
- •negative test result for the presence of IgM and IgG antibodies to SARS CoV2 by enzyme immunoassay;
- •negative test result for COVID-2019, determined by PCR at the screening session;
- •The absence of a history COVID-2019;
- •No contact of the study subject with COVID-2019 patients for at least 14 days prior to inclusion in the study (according to the study participant);
- •Consent to use effective methods of contraception during the entire period of participation in the study;
- •A negative test for the presence of narcotic and psychoactive agents in urine at the screening visit;
- •A negative test for alcohol at screening visit;
- •negative pregnancy test (performed for women with preserved reproductive potential)
- •No history of severe postvaccinal reactions or postvaccinal complications after the use of immunobiological drugs;
- •absence of acute infectious and/or respiratory diseases for at least 14 days prior to inclusion in the study.
排除标准
- •any vaccination/immunization performed within 30 days prior to inclusion in The study;
- •therapy with steroids (with the exception of hormonal contraceptives and drugs used as hormone replacement therapy for menopause) and/or immunoglobulins or other blood products that did not end 30 days before inclusion in the study;
- •Therapy immunosuppressive drugs, which ended less than 3 months before inclusion in the study;
- •Subjects of the female gender during pregnancy or breastfeeding;
- •Postponed less than one year before inclusion in the study, acute coronary syndrome or stroke;
- •Tuberculosis, chronic systemic infections;
- •burdened allergic history (the presence in the history of information about anaphylactic shock, Quincke's edema, polymorphic exudative eczema, atopy, serum sickness), hypersensitivity or allergic reactions to the introduction of immunobiological drugs, known allergic reactions to the components of the drug, exacerbation of allergic diseases on the day of inclusion in the study;
- •the presence of a history of neoplasms (ICD codes C00-D09);
- •donation of blood or plasma (450 ml or more) less than 2 months before inclusion in the study;
- •Splenectomy in history;
- •Neutropenia (decrease in the absolute number of neutrophils less than 1000/mm3), agranulocytosis, significant blood loss, severe anemia (hemoglobin less than 80 g/l), a history of immunodeficiency for 6 months before inclusion in the study;
- •Subjects with an active form of the disease caused by the human immunodeficiency virus, syphilis, hepatitis B and C;
- •Anorexia, protein deficiency of any origin;
- •extensive tattoos at the sites of drug administration (deltoid muscle area), which do not allow to assess the local response to the introduction of ILP;
- •Alcoholism and drug addiction in history;
- •Consists on the account at the psychiatrist;
- •subject's participation in any other interventional clinical trial within 90 days prior to the start of this study;
- •any other condition of the research subject that, in the opinion of the research doctor, may prevent the completion of the study in accordance with The Protocol;
- •staff of research centers and other employees directly involved in the research (members of the research team) and their families.
- •severe comorbid diseases that, in the opinion of the research doctor, may prevent participation in the study.
结局指标
主要结局
Number of Participants With Adverse Events
时间窗: through the whole study, an average of 180 days
Determination of Number of Participants With Adverse Events
Changing of antibody levels against the SARS-CoV-2 glycoprotein S in 42 days
时间窗: at days 0, 21, 28, 42
Determination of antibody levels against the SARS-CoV-2 glycoprotein S measured by an ELISA vs. baseline values
次要结局
- Changing of antigen-specific cellular immunity level(Time Frame: at days 0,28)
- Changing of of virus neutralizing antibody titer(at days 0, 28, 42)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
An Open Study of the Safety, Tolerability and Immunogenicity of the Drug "Gam-COVID-Vac" Vaccine Against COVID-19Preventive Immunization COVID-19NCT04436471Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation38
已完成
1 期
An Open Study of the Safety, Tolerability and Immunogenicity of "Gam-COVID-Vac Lyo" Vaccine Against COVID-19Preventive Immunization COVID-19NCT04437875Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation38
尚未招募
2 期
Study of Monoclonal Antibodies for Early Etiotropic Therapy for Coronavirus Infection Caused by the SARS-CoV-2 VirusCOVID-19NCT05729360Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation30
招募中
早期 1 期
Study of KRAS Neoantigen mRNA Vaccine (ABO2102) in Patients With KRAS -Mutated Solid TumorsNCT06577532Ruijin Hospital56
已完成
3 期
Study of the EpiVacCorona Vaccine With the Involvement of Volunteers Aged 60 Years and AboveCovid19NCT05021016Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector"150